9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Epithelioid Mesothelioma

Estimated Enrollment: 136

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I),  Progression-free survival (Phase II),  Overall survival (Phase II), Response (Phase II)

Interventions: Cediranib Maleate, Cisplatin

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Investigator),Primary Purpose: Treatment

Primary Completion Date: June 1, 2018

Completion Date:

Last  Posted Date: January 17, 2019

Location: Highlands Oncology Group-Rogers, Rogers, Arkansas, United States

Website Link: https://ClinicalTrials.gov/show/NCT01064648

Was this article helpful?
Dislike 0